Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma

Ehinger, Erik LU ; Kopecky, Jan LU orcid ; Darabi, Anna LU ; Visse, Edward LU ; Edvardsson, Charlotte LU ; Tomasevic, Gregor LU ; Cederberg, David LU ; Belting, Mattias LU ; Bengzon, Johan LU and Siesjö, Peter LU orcid (2023) In BMC Neurology 23(1).
Abstract

Purpose: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ). Experimental studies suggest that antisecretory factor (AF), an endogenous protein with proposed antisecretory and anti-inflammatory properties, may potentiate the effect of TMZ and alleviate cerebral edema. Salovum is an egg yolk powder enriched for AF and is classified as a medical food in the European Union. In this pilot study, we evaluate the safety and feasibility of add-on Salovum in GBM patients. Methods: Eight patients with... (More)

Purpose: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ). Experimental studies suggest that antisecretory factor (AF), an endogenous protein with proposed antisecretory and anti-inflammatory properties, may potentiate the effect of TMZ and alleviate cerebral edema. Salovum is an egg yolk powder enriched for AF and is classified as a medical food in the European Union. In this pilot study, we evaluate the safety and feasibility of add-on Salovum in GBM patients. Methods: Eight patients with newly diagnosed, histologically confirmed GBM were prescribed Salovum during concomitant radiochemotherapy. Safety was determined by the number of treatment-related adverse events. Feasibility was determined by the number of patients who completed the full prescribed Salovum treatment. Results: No serious treatment-related adverse events were observed. Out of 8 included patients, 2 did not complete the full treatment. Only one of the dropouts was due to issues directly related to Salovum, which were nausea and loss of appetite. Median survival was 23 months. Conclusions: We conclude that Salovum is safe to use as an add-on treatment for GBM. In terms of feasibility, adherence to the treatment regimen requires a determined and independent patient as the large doses prescribed may cause nausea and loss of appetite. Trial registration: ClinicalTrials.gov NCT04116138. Registered on 04/10/2019.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antisecretory factor, Glioblastoma, Novel treatments against glioblastoma, Salovum
in
BMC Neurology
volume
23
issue
1
article number
76
publisher
BioMed Central (BMC)
external identifiers
  • scopus:85148358231
  • pmid:36803465
ISSN
1471-2377
DOI
10.1186/s12883-023-03119-4
language
English
LU publication?
yes
id
c4ea1360-d6e2-4efc-9640-afd6d5886cee
date added to LUP
2023-03-01 15:52:28
date last changed
2024-06-13 16:07:10
@article{c4ea1360-d6e2-4efc-9640-afd6d5886cee,
  abstract     = {{<p>Purpose: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ). Experimental studies suggest that antisecretory factor (AF), an endogenous protein with proposed antisecretory and anti-inflammatory properties, may potentiate the effect of TMZ and alleviate cerebral edema. Salovum is an egg yolk powder enriched for AF and is classified as a medical food in the European Union. In this pilot study, we evaluate the safety and feasibility of add-on Salovum in GBM patients. Methods: Eight patients with newly diagnosed, histologically confirmed GBM were prescribed Salovum during concomitant radiochemotherapy. Safety was determined by the number of treatment-related adverse events. Feasibility was determined by the number of patients who completed the full prescribed Salovum treatment. Results: No serious treatment-related adverse events were observed. Out of 8 included patients, 2 did not complete the full treatment. Only one of the dropouts was due to issues directly related to Salovum, which were nausea and loss of appetite. Median survival was 23 months. Conclusions: We conclude that Salovum is safe to use as an add-on treatment for GBM. In terms of feasibility, adherence to the treatment regimen requires a determined and independent patient as the large doses prescribed may cause nausea and loss of appetite. Trial registration: ClinicalTrials.gov NCT04116138. Registered on 04/10/2019.</p>}},
  author       = {{Ehinger, Erik and Kopecky, Jan and Darabi, Anna and Visse, Edward and Edvardsson, Charlotte and Tomasevic, Gregor and Cederberg, David and Belting, Mattias and Bengzon, Johan and Siesjö, Peter}},
  issn         = {{1471-2377}},
  keywords     = {{Antisecretory factor; Glioblastoma; Novel treatments against glioblastoma; Salovum}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{BMC Neurology}},
  title        = {{Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma}},
  url          = {{http://dx.doi.org/10.1186/s12883-023-03119-4}},
  doi          = {{10.1186/s12883-023-03119-4}},
  volume       = {{23}},
  year         = {{2023}},
}